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Injection of active vitamin D is associated with better
survival of patients receiving chronic hemodialysis. Since in
many countries oral active vitamin D administration is the
most common form of treatment for secondary
hyperparathyroidism we determined the survival benefit of
oral active vitamin D in hemodialysis patients from six Latin
America countries (FME Registers as part of the CORES
study) followed for a median of 16 months. Time-dependent
Cox regression models, after adjustment for potential
confounders, showed that the 7,203 patients who received
oral active vitamin D had significant reductions in overall,
cardiovascular, infectious and neoplastic mortality compared
to the 8,801 patients that had not received vitamin D.
Stratified analyses found a survival advantage in the group
that had received oral active vitamin D in 36 of the 37 strata
studied including that with the highest levels of serum
calcium, phosphorus and parathyroid hormone. The survival
benefit of oral active vitamin D was seen in those patients
receiving mean daily doses of less than 1 lg with the highest
reduction associated with the lowest dose. Our study shows
that hemodialysis patients receiving oral active vitamin D had
a survival advantage inversely related to the vitamin dose.
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Calcitriol deficiency is a common medical condition among
patients with chronic kidney disease.1,2 Calcitriol, the most
active form of vitamin D, increases intestinal calcium
absorption, effectively suppresses parathyroid hormone
(PTH) secretion, prevents skeletal complications, and it
has been the standard therapy for secondary hyperpara-
thyroidism for more than two decades.3 Calcitriol
administration may also result in an elevation of serum
calcium and phosphorus levels, which may facilitate vascular
calcification and death.4 Conversely, other studies have
shown that the use of calcitriol and other forms of vitamin
D derivatives is associated with improved survival in patients
with cancer or infections.5–7 More recently, a large historical
cohort study has demonstrated a significant survival
advantage of 20% in chronic hemodialysis patients receiving
injectable active vitamin D.8 In many countries, the most
common form of administration of active vitamin D as
treatment for secondary hyperparathyroidism is the oral
route instead of the injectable form. Accordingly, this study
examined the potential survival effect of oral active vitamin
D in a large cohort of hemodialysis patients.
RESULTS
Baseline characteristics of the group that received oral active
vitamin D (n¼ 7203) and the group that did not receive it
(n¼ 8801) are shown in Table 1. Baseline serum levels of
phosphorus and calcium-phosphorus product were signifi-
cantly lower, whereas PTH was higher in the oral active
vitamin D users. Patients who did not receive oral active
vitamin D were older; and there were more diabetics.
Throughout the whole follow-up there were 3110 deaths
and 1792 lost to follow-up due to: renal transplantation
(39.0%), switch to peritoneal dialysis (29.5%), voluntary
withdrawal from therapy (16.1%), recovery of renal function
(9.6%), unknown circumstances (3.7%), and transfer to a
non-Fresenius dialysis unit (2.1%).
Survival analysis
The overall mortality rate was 19.4%; Venezuela (25.4%),
Argentina (22.7%), Mexico (16.2%), Brazil (15.7%), Chile
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(14.6%); and Colombia (13.8%). The crude analysis using
the Kaplan–Meier curve showed significant reduction of
mortality risk in patients who received oral active vitamin D
within 1 year compared to these who did not receive it
(Po0.001, Figure 1). As the Figure 2 shows, the association
of oral active vitamin D use with mortality reduction did not
vary by country, including countries with both high and low
overall death rates.
As primary exposure was time dependent and the
Kaplan–Meier curve might have overestimated the survival
benefit, additional analyses (models 2–5 in Table 2) were
carried out after adjustment for potential confounders. There
were no differences between the adjusted and unadjusted
mortality risk among those patients who did and did not
receive vitamin D therapy. Multivariable adjusted analyses
revealed that patients who received oral active vitamin D had
a significant 45% (hazard ratio, 0.55; 95% confidence interval
(CI), 0.49–0.63) lower overall mortality risk compared to
patients who did not receive oral active vitamin D (Table 2).
Furthermore, cardiovascular, infectious, and neoplastic
mortality risk were 45 (hazard ratio, 0.55; CI, 0.45–0.67),
48 (hazard ratio, 0.52; CI, 0.39–0.68), and 47% (hazard ratio,
0.53; CI, 0.34–0.82) lower, respectively, in patients on oral
active vitamin D.
Similar results were observed when center instead of
country was used as covariate in the multivariate analysis.
As once the patient was withdrawn from hemodialysis, no
additional information about mortality was obtained, a
Table 1 | Baseline data before the oral active vitamin D treatmenta
Characteristics Without Vitamin D With Vitamin D P-value
(N=8801) (N=7203)
Age (year) 55.6 (16.0) 53.9 (15.9) o0.001
Male patients (%) 58.4 58.3 0.81
Cause of renal failure (% of patients) o0.001
Diabetes 28.7 24.5
Nephroangioesclerosis 15.8 20.9
Glomerulonephritis 9.9 12.6
Other 45.6 42.0
Vascular access (% of patients) o0.001
Catheter 25.9 22.0
Fistula 27.8 50.0
Graft 3.3 5.8
Unknown 43.0 22.2
Weekly hours on dialysis (hour) 11.8 (0.9) 11.9 (0.7) o0.001
Time on dialysis (year) 0.9 (2.4) 1.5 (3.3) o0.001
Time on dialysis (year)b 0 (0–0.3) 0 (0–1.1) o0.001
Dialysate calcium (mEq/l) 3.1 (0.4) 3.1 (0.6) 0.61
Weight (kg) 63.8 (14.3) 64.2 (14.2) 0.10
Calcium (mg per 100 ml) 9.1 (0.9) 9.1 (0.9) o0.001
Body mass index (kg/m2) 23.7 (4.7) 23.8 (4.6) 0.11
Phosphorus (mg per 100 ml) 5.0 (1.5) 4.9 (1.3) o0.001
Calcium-Phosphorus product (mg2 per (100 ml)2) 45.6 (14.4) 44.6 (13.2) o0.001
Parathyroid hormone (pg/ml) 213 (284) 421 (393) o0.001
Parathyroid hormone (pg/ml)b 123 (57–247) 324 (169–534) o0.001
Albumin (g per 100 ml) 3.7 (0.6) 3.7 (0.5) o0.001
Total cholesterol (mg per 100 ml) 185 (53) 185 (50) 0.93
Hemoglobin (g per 100 ml) 9.1 (1.8) 9.6 (1.8) o0.001
Ferritin (ng/ml) 433 (389) 449 (383) 0.044
Ferritin (ng/ml)b 320 (159–590) 340 (164–619) 0.019
Creatinine (mg per 100 ml) 7.8 (2.98) 8.2 (2.8) o0.001
Kt/Vc 1.37 (0.3) 1.3 (0.3) o0.001
Calcium acetate (g) 66.3 (428.1) 81.7 (410.3) 0.48
Calcium acetate (g)d 25 (12–54) 32 (12–64) o0.005
Calcium carbonate (g) 210 (1,454) 195 (1,324) 0.72
Calcium carbonate (g)d 30 (12–65) 49 (22–100) o0.001
Aluminum hydroxide binders (g) 4.6 (9.6) 4.5 (7.0) 0.91
Aluminum hydroxide binders (g)d 1.0 (0.02–6) 1.0 (0.01–5) 0.73
aBaseline laboratory values represent the mean and standard deviation value over the 3 months before 90 days after initiating dialysis for the non-vitamin D group and the 3
months before initiating vitamin D therapy in the vitamin D group. The mean and standard deviation of baseline parathyroid hormone was obtained over 6 months.
bBaseline time on dialysis, parathyroid hormone and ferritin represent the median and interquartile range. In the case of the parathyroid hormone, the median and
interquartile range were obtained over 6 months. A Mann–Whitney U-test has been made for comparison between groups.
cDelivered Kt/V=ln (R0.008 t)+(43.5R)UF/W, where R=post dialysis/pre dialysis blood urea nitrogen, t=dialysis hours, UF=pre dialysis-post dialysis weight change, and
W=post dialysis weight.
dCalcium acetate, calcium bicarbonate, and aluminum hydroxide binders represent the median and interquartile range. A Mann–Whitney U-test has been made for
comparison between groups. Calcium acetate and calcium bicarbonate as non-aluminic phosphate binders data were available in 4560 patients and aluminum hydroxide
binders were available in 338 patients.
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sensitivity analysis was carried out to examine the potential
impact of the censored patients. The sensitive analysis
revealed that censored patients (hazard ratio, 0.58; CI,
0.51–0.67) did not differ from those who were not censored
(hazard ratio, 0.55; CI, 0.49–0.63) and the association of
vitamin D with reduced mortality did not differ when
participants were considered to have died at the time of
censoring (hazard ratio, 0.58; CI, 0.53–0.65). The 244 patients
censored, because they switched from oral active vitamin D
to injectable active vitamin D, also showed a survival benefit
(hazard ratio, 0.63; CI, 0.42–0.93).
The analysis of prevalent and incident hemodialysis patients
showed also a significant reduction in the mortality risk rates
in both groups. Overall mortality (hazard ratio, prevalent: 0.51;
CI, 0.40–0.66 and hazard ratio, incident: 0.57; CI, 0.50–0.67),
cardiovascular mortality (hazard ratio, prevalent: 0.59; CI,
0.40–0.88 and hazard ratio, incident: 0.53; CI, 0.42–0.67),
infectious mortality (hazard ratio, prevalent: 0.61; CI, 0.37–1.02
and hazard ratio, incident: 0.50; CI, 0.38–0.75), and neoplastic
mortality (hazard ratio, prevalent: 0.33, CI, 0.13–0.84 and
hazard ratio, incident: 0.56; CI, 0.34–0.75). The association of
vitamin D with reduced mortality was not altered when
socioeconomic status was added to analyses in a subset of
participants with available data (n¼ 6961 from Argentina).
Stratified analysis
As it has been mentioned, certain baseline characteristics
differed between the two groups (Table 1). Patients who
received oral active vitamin D treatment were 1.7 years
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Figure 1 | Kaplan-Heier analysis of survival. (a) Survival curve of
patients treated with oral active vitamin D (in dark; deaths,
n¼ 1280; total number, n¼ 7203) compared with the untreated
patients (in grey; deaths, n¼ 1830; total number, n¼ 8801).
The crude analysis was carried out by the Kaplan–Meier curves.
(b) Analysis restricted to those patients who started oral active
vitamin D therapy within 90 days.
Characteristic
Calcium (mg/100 ml)
8.70
>9.37
8.70–9.37
409
351
376
1898
2070
2079
21.5
17.0
18.1
Phosphorus (mg/100 ml)
4.27
>5.33
4.27–5.33
393
386
352
1930
2210
1954
20.4
17.5
18.0
Parathyroid hormone (pg/mL)
118
>326
118–326
340
273
330
1680
1664
1679
20.2
16.4
19.7
Creatinine (mg/100 ml)
6.5
>8.9
6.5–8.9
475
264
403
1935
2198
1999
24.5
12.0
20.2
Albumin (g/100 ml)
3.5
>3.9
3.5–3.9
508
270
364
2031
2090
2006
25.0
12.9
18.1
Hemoglobin (g/100 ml)
8.47
>10
8.47–10
381
362
399
1810
2259
2059
21.0
16.0
19.4
Age (years)
Diabetes
50
50–64
65–74
75 +
204
328
223
387
413
729
1474
4659
28.0
15.6
Yes
No
Gender
679
463
3689
2447
18.4
18.9
Male
Female
Vascular access
268
530
126
224
25.2
15.3
29.4
17.5
1063
3454
428
1280
Catheter
Female
Graft
Unknown
Country
758
338
45
23.4
13.7
11.1
3239
2472
404
Argentina
Brazil
Colombia
Comorbidities
392
278
196
276
10.7
36.0
32.6
25.2
0.2
Favors vitamin D Favors no
vitamin D
0.4 0.6 0.8 1.0 1.2 1.4
3660
773
601
1096
No
Vascular
Infectious
Other
2296
1199
627
1999
8.9
27.4
35.6
19.4
No. of
deaths
Total
no. Percent Hazard ratio
Figure 2 | Hazard ratios for mortality risk associated with
oral active vitamin D treatment stratified by exposure
characteristic. Each result reflects a multivariable adjusted model
(age, gender, diabetes status, weekly hours on dialysis, Kt/V,
center, baseline laboratory values, and comorbidity) according to
Table 2. Percentage represents fraction of deaths within each
stratum, circles represent the point estimates, and horizontal lines
represent 95% confidence intervals. Reference category for each
analysis is the corresponding group that did not receive oral
active vitamin D.
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younger with a 4.2% lower prevalence of diabetes. Other
baseline characteristics such as body weight, serum creati-
nine, serum albumin, and serum hemoglobin levels were
higher in patients who received oral active vitamin D
treatment. In order to minimize the confounding effect of
these baseline differences, we performed stratified analyses
(Figure 2). Within each level of the stratified variables, the
analysis was multivariable adjusted for all the potential
confounders included in the final model shown in Table 2. In
36 of the 37 strata studied, we observed a significant survival
advantage in the group that had received oral active vitamin
D, including the stratum of patients with the highest serum
calcium (tertile 3: 49.37 mg per 100 ml), phosphorus
(tertile 3: 45.33 mg per 100 ml), and PTH levels (tertile 3:
4326 pg/ml).
The stratification of the propensity score in tertiles
confirmed a significant survival advantage in the group that
had received oral active vitamin D (tertile 1—hazard ratio:
0.65, CI: 0.51–0.83; tertile 2—hazard ratio: 0.51, CI:
0.41–0.65; tertile 3—hazard ratio: 0.44, CI: 0.35–0.55).
Secondary analysis
To further examine the effect of different doses of oral active
vitamin D, we analyzed the results of the four preestablished
categories using unadjusted and adjusted analyses, using as
covariates all those included in model 5 in Table 2. Patients
who received oral active vitamin D in a mean daily dose
lower than 0.25 mg, between 0.25–0.50 mg, and 0.51–1 mg
showed a mortality reduction of 54% (hazard ratio, 0.46; CI,
0.39–0.54), 42% (hazard ratio, 0.58; CI, 0.49–0.70), and 36%
(hazard ratio, 0.64; CI, 0.50–0.83), respectively. However, no
significant reduction in mortality was observed with a mean
daily dose higher than 1 mg (hazard ratio, 0.83; CI, 0.58–1.19;
Figure 3). In the lower dose group (o0.25 mg) the cumulative
dose was 78 mg and the duration of treatment was 540 days,
meanwhile in the highest dose group (41 mg) the cumulative
dose was nine times higher (686 mg) and the duration of
treatment shorter (314 days).
We also performed independent analyses in those patients
whom the current clinical practice K/DOQI guidelines
recommended the use of active vitamin D metabolites
(baseline intact PTH 4300 pg/ml and Calcium-Phosphorus
product o55 mg2 per (100 ml)2).9 A mean daily dose lower
than 0.25 mg (mean 0.15 mg) and also a dose between 0.25 and
0.50 mg (mean 0.34 mg) significantly reduced the mortality
risk rate by 55% (hazard ratio, 0.45; CI, 0.31–0.65) and by
60% (hazard ratio, 0.40; CI, 0.27–0.60), respectively, com-
pared to oral active vitamin D nonusers. No significant
reduction in mortality risk was found in patients receiving
either a mean daily dose between 0.51 and 1 mg (mean 0.67;
hazard ratio, 0.77; CI, 0.49–1.23) or a dose of more than 1mg
(mean 1.69; hazard ratio, 1.14; CI, 0.56–2.33). The analyses of
prevalent and incident patients showed similar patterns;
however, patients who started oral active vitamin D
treatment within the first 90 days showed a slightly better
results than patients who started the treatment later (hazard
ratio, 0.57; CI, 0.48–0.68 vs hazard ratio, 0.74; CI, 0.62–0.87,
respectively).
DISCUSSION
In the past few years, the detrimental or beneficial effect of
active vitamin D treatment on the cardiovascular system and
the risk of mortality has been a controversial issue. The
concern about the harmful effect of vitamin D derivatives is
mainly based on the fact that in experimental models high
doses of vitamin D metabolites have shown to increase
vascular calcifications10,11 and some human data also support
this notion.12 On the other hand, experimental studies have
shown that low and more physiological dose of active vitamin
D may have a cardioprotective effect.13,14 Observational
Table 2 | Cox proportional hazard analysis of mortality with oral vitamin D
Model Covariates No. of patients Hazard ratio 95% confidence interval
1 Unadjusted 16,004 0.58 0.54–0.63
2 Age, gender, diabetes status, and time on dialysis 15,648 0.60 0.56–0.65
3 Model 2 plus Kt/V, and country 11,082 0.52 0.47–0.58
4 Model 3 plus vascular access, baseline values, and time-varying variablesa 6136 0.58 0.51–0.65
5 Model 4 plus comorbidities 6136 0.55 0.49–0.63
Time-varying variables were serum calcium, phosphorus, and parathyroid hormone.
aThe baseline values quoted were weight, albumin, creatinine, and hemoglobin.
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Figure 3 | Hazard ratio for mortality risk according to the
different categories of daily mean intake of oral active
vitamin D. This analysis was unadjusted (white bars) and adjusted
by the covariates included in model 5 in Table 2 (grey bars).
Reference category is the group that did not receive oral active
vitamin D. The number of patients in each category of daily mean
intake of oral active vitamin D was included in the columns. PTH
median with interquartile range in the different categories of daily
mean intake of oral active vitamin D (from lowest to highest dose)
were 303 (182–462), 326 (149–539), 465 (255–724), and 491
(174–906) pg/ml, respectively.
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studies in patients on dialysis have also demonstrated
morbidity15 and a cardiovascular16 or overall mortality
advantage8,17,18 for patients who are treated with active
vitamin D derivatives vs those without treatment.
In addition, one epidemiological study reported a survival
advantage when patients receiving new vitamin D analogs
were compared to patients receiving an injectable calcitriol
formulation.19 However, this effect was less pronounced in a
recent paper.18 It was speculated that the potential survival
advantage was mediated by the described less calcemic and
phosphatemic effects of the new analogs, but the survival
benefit was sustained for almost all levels of phosphorus and
calcium.18,19
Although oral active vitamin D treatment is widely used,
till date there is only one paper investigating survival using
oral active vitamin D in a small cohort of patients.16 The
results of our study show for the first time a significant
survival advantage of oral active vitamin D in a larger cohort
of chronic hemodialysis patients. Similarly to others,8
this advantage of oral active vitamin D appeared to be
independent of other potential risk factors and confounders.
In fact, the reduction in mortality risk was observed in 36 of
the 37 multivariate strata analyzed, including baseline serum
calcium, phosphorus, and PTH levels. The only stratum
which did not achieve statistical significance was the one
related to the use of grafts as vascular access, possibly due to
the low number of patients.
Despite the potentially higher bioavailability of the
injectable form of vitamin D compared to the oral form,
our data show a higher reduction in the overall mortality risk
compared to the results obtained with injectable active
vitamin D.8 The biological significance on survival benefit for
oral active vitamin D users merits a detailed analysis.
The positive results in all causes of mortality suggest that
the beneficial effect of active vitamin D is beyond its effect on
calcium-phosphorus metabolism. In recent years, several
experimental studies have demonstrated, among other
actions, an important role of active vitamin D in the
suppression of cell growth and regulation of immune
response.20,21 Moreover, nutritional and epidemiological
evidence has linked abnormalities in the vitamin D system
to susceptibility to infections, autoimmune diseases, and
cancer.22–24 Similarly in our study, neoplastic and infectious
mortality were significantly reduced (47 and 48%, respec-
tively) in patients receiving oral active vitamin D. Moreover,
for neoplastic mortality risk this effect was more marked in
patients who spent more time on dialysis (prevalent
hemodialysis patients, 67%; incident hemodialysis patients,
44%), suggesting a long-term benefit of active oral vitamin D.
Besides these positive survival effects, the benefit of oral
active vitamin D for the cardiovascular system is a
controversial issue. It is well known that high doses of active
vitamin D increase serum calcium and serum phosphorus,
and also suppress serum PTH favoring through different
mechanisms vascular calcification and mortality.10–12,25,26
Conversely, physiological doses of active vitamin D have
shown protective cardiovascular effects reducing the inflam-
matory response to cardiovascular injury, the myocardial cell
hypertrophy and proliferation, and the renin-angiotensin
system activation.27 As it has been said, part of these
paradoxical effects of vitamin D can be explained by the
different dose of active vitamin D used. High pharmacolo-
gical doses may favor and precipitate vascular calcifications
whereas more physiological doses may have protective effects.
Our study shows that mean daily doses of oral active
vitamin D lower than 1 mg showed a significant benefit in
survival rate. Interestingly, the reduction in mortality risk
was even seen at the lowest PTH tertile where a tendency to a
higher mortality risk has been described,28 and also, like
others, with high serum and phosphorus levels.19 In fact, a
mean daily dose of oral active vitamin D lower than 0.25 mg
was able to reduce the mortality risk by 53% in patients with
PTH lower than 150 pg/ml (hazard ratio, 0.47; CI, 0.33–0.66)
independently of serum calcium or phosphorus levels (data
not shown). On the contrary, higher doses of oral active
vitamin D did not have any effect in survival probably, in
part, due to the increments in serum phosphorus levels
observed in this group. In fact, during the whole follow-up
period the mean phosphorus levels of the higher dose group
was significantly higher (5.34±1.24 mg per 100 ml) than the
other groups. This fact may partially explain the greater
survival benefit with intravenous paricalcitol compared to
calcitriol found in previous studies.19 Similarly, other authors
have found a dose-dependent beneficial effect with pari-
calcitol with the lowest doses,17 potency equivalent with the
daily dose of our study. However, it is necessary also to
consider that in our study the reduced number of patients in
the higher dose group is a limitation in order to give a strong
value to this finding.
There were some differences in the results obtained in
incident and prevalent patients. Prevalent patients were
younger (52 (16) vs 56 (16) years old) and obtained benefits
in survival with doses of oral active vitamin D up to 1 mg per
day, whereas in incident patients the beneficial effect was seen
only up to 0.50 mg per day. In addition, prevalent patients
also showed better outcomes regarding neoplastic mortality
compared to incident patients. Regarding the doses, the
whole set of results is consistent with the fact that lower doses
which results in lower cumulative dose of oral active vitamin
D are associated with more benefits in survival despite a
more prolonged time of exposure.
The survival benefit of oral active vitamin D treatment
were consistent in all centers and across countries despite the
differences in mortality rates within each country described
in the results.
Our study shows for the first time a survival beneficial
effect of oral active vitamin D in a large cohort of
hemodialysis patients followed up to 4 years, however, these
interesting and encouraging results may have some limita-
tions. It could have happened that patients with lower
calcitriol and calcidiol serum levels were those who benefited
most from oral active vitamin D treatment. Nevertheless,
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even if this would have been the case, we still can claim a
benefit of oral active vitamin D for all patients. Our study
cannot rule out a possible influence of 25(OH)D3 (calcidiol)
levels, a form of vitamin D that has—among others—also
been related to improved outcomes.29,30 The patients
included in our study did not receive this form of vitamin
D, and serum calcidiol and calcitriol levels were not
measured. Calcidiol insufficiency has been reported world-
wide but there are no studies evaluating mortality.
Although, at baseline the mean serum calcium and
phosphorus was significantly higher and the PTH lower in
the non-oral active vitamin D users, this fact is expected in
studies of large populations even though the magnitude of
the differences are small. Clinically relevant differences were
only present when there were differences in PTH (Figure 2).
In any case, these findings reflect that oral active vitamin D
was adequately prescribed, as patients with moderately high
levels of serum calcium and phosphorus and with no
important serum PTH elevations did not receive oral active
vitamin D treatment. In fact, the mean daily dose of oral
active vitamin D used was related with the median serum
PTH levels as stated in Figure 3.
We are also aware that some measured (Table 1) and
unmeasured confounders (such as bone turnover markers,
vascular calcification, inflammatory status, vitamin D
receptor gene polymorphisms, or even socioeconomic
status—only marginally addressed in this study), or other
biases favoring the vitamin D-treated group cannot be
completely excluded, despite the complete strata analysis
carried out. Even considering the consistent results obtained
using the propensity score, we cannot fully exclude some
effect of confounding by indication, a common limitation in
observational studies. In fact, the risk for confounding by
indication may be increased by use of covariate data obtained
at baseline rather than at the time of vitamin D initiation.
Although a sensitivity analysis was carried out, it does not
fully compensate the missing mortality data from part of the
study population. Finally, even though it was not possible to
standardize mortality, the adjustment by country and center
should have balanced the results.
In summary, our study found that hemodialysis patients
receiving oral active vitamin D showed a survival advantage.
This biological benefit was seen after several stratified
analyses, including different strata of calcium, phosphorus,
and PTH levels and it seems to be inversely related to the
vitamin D dose, observing a better survival with the lower
doses.
MATERIALS AND METHODS
The study was performed in a historical cohort of chronic
hemodialysis patients from six Latin American countries (Argentina,
Brazil, Colombia, Chile, Mexico, and Venezuela) from the CORES
study (Control of Renal Osteodystrophy in South America), who
started hemodialysis, three times a week (98.8%) and two times a
week (1.2%), in 183 different dialysis facilities associated or operated
by Fresenius Medical Care. The entire study population (n¼ 22,230)
consisted of patients older than 18 years who either initiated
hemodialysis (incident patients—72.4% of the cohort) or were
already on hemodialysis (prevalent patients—27.6% of the cohort)
after 1 January 2000. Patients were followed for a period of time
between 3 and 54 months (median 16 months) until 30 June 2004 or
until they were lost to follow-up.
During the study period and once the patient was admitted to
the hemodialysis center, demographic, clinical, laboratory, and other
general data were collected prospectively and entered into a central
database updated by medical personnel and stored by Fresenius
Medical Care (FME register). From this database, the following data
were analyzed: age, gender, weight, country, date of first dialysis,
vascular access, primary cause of renal failure, dose of dialysis,
medications administered during each hemodialysis session (name,
date, dose, and route of administration), laboratory tests, and
comorbidities occurring throughout the follow-up period. All
missed hemodialysis treatments (for example, because of hospita-
lization or noncompliance) and all permanent discharges (for
example, transplantation, voluntary withdrawal from therapy,
transfer to a non-Fresenius dialysis unit, change to peritoneal
dialysis, or lost to follow-up) were also analyzed. Deaths were
defined using the International Classifications of Diseases (ICD-10)
and they were grouped and classified according to the Table 3.
The non-aluminic phosphate binders used in this study were
calcium acetate and calcium carbonate; neither sevelamer nor
lanthanum carbonate were used. All the collected data were checked
prospectively to ensure their accuracy and completeness. The study
met the privacy standards implements by Fresenius with a waiver for
informed consent.
Statistical analysis
Initial analysis. Between January 2000 and June 2004, 22,230
patients who initiated chronic hemodialysis in all the Fresenius
dialysis facilities were included in the study. A total of 169 patients
(0.8%) receiving only injectable active vitamin D or other
formulations different to calcitriol (1,25(OH)2D3) or alphacalcidol
(1-a(OH)D3) were excluded from the analysis. Therefore, this study
includes only the analysis of patients receiving calcitriol or
alphacalcidol referred in the paper as ‘oral active vitamin D’. For
the follow-up, data were censored if patients changed from oral
active vitamin D to injectable active vitamin D type (n¼ 244), but
not if vitamin D was interrupted or discontinued. Also 6057
(27.2%) patients who remained less than 90 days on chronic
hemodialysis were excluded from the analysis. The reasons for these
exclusions were: beginning of hemodialysis after April 2004 (41.8%);
death (29.3%); switch to peritoneal dialysis (11.5%); recovery of
renal function (7.1%); voluntary withdrawal from therapy (4.7%);
unknown circumstances (3.3%); and renal transplantation (2.3%).
During the entire study period, 7203 (45.0%) of the 16,004
remaining patients received oral active vitamin D. Among them,
6962 patients (96.7%) received calcitriol (Rocaltrol, Roche Pharma-
ceuticals, Nutley, New Jersey, USA and Calcitriol Purissimus, Buenos
Aires, Purissimus, Argentina), 212 patients (2.9%) were switched
from calcitriol to alphacalcidol or vice versa and 29 patients (0.4%)
received only alphacalcidol (Etalpha, Leo Pharma Inc., Plantation,
Florida, US). Patients receiving oral active vitamin D for a period of
less than 1 month (n¼ 598) were considered nonusers of oral active
vitamin D for analysis purposes. Of patients who were treated with
oral active vitamin D, 53% had started treatment within 90 days of
initiating chronic hemodialysis, 69% within 180 days, and 85%
within 365 days; the remaining 15% had started treatment after 1
year on hemodialysis. Oral active vitamin D exposure was studied as
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Table 3 | International classification of diseases and related health problems (10th revision)
Vascular
Diseases of the circulatory system
K I05–I09 Chronic rheumatic fever
K I10–I15 Hypertensive diseases
K I20–I25 Ischemic heart diseases
K I26–I28 Pulmonary heart disease and disease of pulmonary circulation
K I30–I52 Other forms of heart disease
K I60–I69 Cerebrovascular diseases
K I70–I79 Diseases of arteries, arterioles, and capillaries
Infectious
Certain infectious and parasitic diseases
K A00–A09 Intestinal infectious diseases
K A15–A19 Tuberculosis
K A30–A49 Other bacterial diseases
K A50–A64 Infectious with a predominantly sexual mode of transmission
K A65–A69 Other spirochetal diseases
K A70–A74 Other diseases caused by chlamydiae
K A75–A79 Rickettsioses
K A80–A89 Viral infections of the central nervous system
K A90–A99 Arthropod-borne viral fevers and viral hemorrhagic lesions
K B00–B09 Viral infections characterized by skin and mucous membrane lesions
K B15–B19 Viral hepatitis
K B20–B24 Human immunodeficiency virus (HIV) disease
K B25–B34 Other viral diseases
K B35–B49 Mycoses
K B50–B64 Protozoal diseases
K B65–B83 Helminthiases
K B90–B94 Sequelae of infectious and parasitic diseases
Diseases of the respiratory system
K J00–J06 Acute upper respiratory infections
K J09–J18 Influenza and pneumonia
K J20–J22 Other acute lower respiratory infectious
Diseases of the skin and subcutaneous tissue
K L00–L08 Infectious of the skin and subcutaneous tissue
Diseases of the musculoskeletal system and connective tissue
K M00–M03 Infectious arthropathies
Diseases of the genitourinary system
K N70–N77 Inflammatory diseases of female pelvic organs
Neoplastic
Neoplams
K C00–C75 Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, hematopoietic, and related tissue
K C76–C80 Malignant neoplasms of ill-defined, secondary, and unspecified sites
K C81–C96 Malignant neoplasms, stated or presumed to be primary, of lymphoid, hematopoietic, and related tissue
K D00–D09 In sity neoplasms
K D10–D36 Benign neoplasms
K D37–D48 Neoplasms of uncertain or unknown behavior
Neurological
Diseases of the nervous system
K G00–G09; G20–G26; G30–G32; G35–G37; G40–G47; G60–G64; G80–G83; G90–G99
Respiratory
Diseases of the respiratory system
K J30–J39; J40–J47; J60–J70; J80–J84; J90–J94; J95–J99
Diabetes
Endocrine, nutritional and metabolic diseases
K E10–E14 Diabetes mellitus
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a time-dependent variable in all analyses. In this manner, if a patient
initiated oral active vitamin D treatment 1 year after initiating the
study, then the 1-year survival before starting therapy was credited
to the group with no treatment. Furthermore, once a patient
received oral active vitamin D for more than 1 month, the patient
remained in the active oral vitamin D group for all further analyses
regardless of the number of doses of oral active vitamin D received
and regardless of any changes in serum calcium and phosphorus that
may have resulted from the oral active vitamin D administration.
The mean time of oral active vitamin D exposure was 13 months.
In order to assure compliance, centers provided the oral active
vitamin D to each individual patient and ensured that patients
swallowed it at the end of the hemodialysis session.
Standard univariate analyses (w2, t-tests, and Mann–Whitney
U-test) were performed, and values were reported as percentages,
mean and standard deviation or median, and the interquartile
range for descriptive purposes. The primary analysis used both,
the Kaplan–Meier curves to examine crude survival and the
Cox proportional hazard ratios to estimate mortality rate ratios
for oral vitamin D users vs nonusers. Patients contributed as person-
time until they underwent kidney transplantation, voluntarily
withdrew from chronic hemodialysis, or reached the end of the
follow-up period, whichever occurred first. Stratum-specific hazard
ratios were examined to test whether there was a statistically
significant effect in each stratum. The Cox model included the
following baseline variables: age, gender, history of diabetes, time on
dialysis, vascular access, weight, blood levels of albumin, hemoglo-
bin, creatinine, and delivered dose of dialysis (Kt/V). To provide a
better estimate of exposure, average of baseline laboratory values
were obtained from all data recorded within the 3 months prior to
the follow-up.
Serum levels of calcium, phosphorus, and PTH (the latter
measured by the Nichols Advantage Chemiluminescence intact
assay) were included in the Cox model as time-dependent variables.
Serum calcium, phosphorus, and PTH reflected baseline levels for
patients who did not receive oral active vitamin D, whereas for
patients who received it, the calcium, phosphorus, and PTH levels
included in the model were those collected before the initiation of
therapy.
In order to account for a possible country effect on the mortality
rate, all the analyses were carried out after adjusting them by
country. Comorbidities were classified according to the ICD-10 and
grouped into vascular, neoplastic, infectious, respiratory, neurolo-
gical, or diabetes according to the Table 3.
Furthermore, in order to get an unbiased estimate of the
treatment effects, we obtained propensity scores in logistic
regression models using as covariates the differences in baseline
characteristics. We divided the cohort in tertiles of propensity scores
and examined the hazard ratio for mortality risk associated with oral
active vitamin D treatment.
Secondary analysis. In addition to the study of oral active
vitamin D intake as a dichotomous variable (yes vs no), the mean
daily intake (total cumulative dose of vitamin D divided by the
number of days on dialysis) of oral active vitamin D was analyzed
and subdivided into four categories: less than a mean of 0.25 mg per
day, between 0.25 and 0.50mg per day, between 0.51 and 1 mg per
day, and more than 1 mg per day. These categories were used to
evaluate the relationship between the dose of oral active vitamin D
and mortality.
All analyses of the data were carried out using SPSS version 12.0
for Windows.
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